| Compassus - Lansing 801 South Waverly Road Suite 200, Lansing, MI, 48917 | |
| (517) 886-8470 |
News Archive
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER Sirolimus-eluting Coronary Stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK.
Skilled Healthcare Group, Inc. today announced its consolidated financial operating results for the three and twelve-month period ended December 31, 2012.
An investigation into factors related to disparities of depression in young adults has found that higher parental education - which has a protective effect for white youth - can also increase the risk of depression for black youth.
This hodgepodge of controls over premiums needs to be backstopped by a national law that would allow the federal government to block unjustified rate increases where state officials lack the authority to do so. Attempts to include such powers in the newly enacted health care reform law failed (5/9).
YM BioSciences Inc., today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology.
› Verified 3 days ago
| Name | Compassus - Lansing |
|---|---|
| Location | 801 South Waverly Road Suite 200, Lansing, Michigan |
| Hospice ID | 231599 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Other |
| Profit Type | FOR PROFIT |
| Accreditation Provider | Community Health Accreditation Partner (CHAP) |
| SSA county code | 220 |
News Archive
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER Sirolimus-eluting Coronary Stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK.
Skilled Healthcare Group, Inc. today announced its consolidated financial operating results for the three and twelve-month period ended December 31, 2012.
An investigation into factors related to disparities of depression in young adults has found that higher parental education - which has a protective effect for white youth - can also increase the risk of depression for black youth.
This hodgepodge of controls over premiums needs to be backstopped by a national law that would allow the federal government to block unjustified rate increases where state officials lack the authority to do so. Attempts to include such powers in the newly enacted health care reform law failed (5/9).
YM BioSciences Inc., today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology.
› Verified 3 days ago
| NPI Number | 1548236557 |
| Organization Name | Hospice Advantage, Llc |
| Address | 801 S Waverly Rd Lansing, Michigan, 48917 |
| Phone Number | (517)886-8470 |
News Archive
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER Sirolimus-eluting Coronary Stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK.
Skilled Healthcare Group, Inc. today announced its consolidated financial operating results for the three and twelve-month period ended December 31, 2012.
An investigation into factors related to disparities of depression in young adults has found that higher parental education - which has a protective effect for white youth - can also increase the risk of depression for black youth.
This hodgepodge of controls over premiums needs to be backstopped by a national law that would allow the federal government to block unjustified rate increases where state officials lack the authority to do so. Attempts to include such powers in the newly enacted health care reform law failed (5/9).
YM BioSciences Inc., today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology.
› Verified 3 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 99.3 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 92.7 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 85.8 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 41.3 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 100.0 | 97.3 |
| Patients who got timely treatment for shortness of breath | 83.3 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 84.7 | 93.3 |
News Archive
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER Sirolimus-eluting Coronary Stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK.
Skilled Healthcare Group, Inc. today announced its consolidated financial operating results for the three and twelve-month period ended December 31, 2012.
An investigation into factors related to disparities of depression in young adults has found that higher parental education - which has a protective effect for white youth - can also increase the risk of depression for black youth.
This hodgepodge of controls over premiums needs to be backstopped by a national law that would allow the federal government to block unjustified rate increases where state officials lack the authority to do so. Attempts to include such powers in the newly enacted health care reform law failed (5/9).
YM BioSciences Inc., today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology.
› Verified 3 days ago
| Home Health Aides | 11.4 |
| Counselors | 3.2 |
| Medical Social Workers | 2.3 |
| Physicians | 0.6 |
| Registered Nurses | 13 |
| Other Personnel | 6.4 |
| Total Employees | 36.9 |
|---|
News Archive
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER Sirolimus-eluting Coronary Stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK.
Skilled Healthcare Group, Inc. today announced its consolidated financial operating results for the three and twelve-month period ended December 31, 2012.
An investigation into factors related to disparities of depression in young adults has found that higher parental education - which has a protective effect for white youth - can also increase the risk of depression for black youth.
This hodgepodge of controls over premiums needs to be backstopped by a national law that would allow the federal government to block unjustified rate increases where state officials lack the authority to do so. Attempts to include such powers in the newly enacted health care reform law failed (5/9).
YM BioSciences Inc., today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology.
› Verified 3 days ago
| Others | 0.5 |
| Total Volunteers | 0.5 |
|---|
News Archive
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER Sirolimus-eluting Coronary Stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK.
Skilled Healthcare Group, Inc. today announced its consolidated financial operating results for the three and twelve-month period ended December 31, 2012.
An investigation into factors related to disparities of depression in young adults has found that higher parental education - which has a protective effect for white youth - can also increase the risk of depression for black youth.
This hodgepodge of controls over premiums needs to be backstopped by a national law that would allow the federal government to block unjustified rate increases where state officials lack the authority to do so. Attempts to include such powers in the newly enacted health care reform law failed (5/9).
YM BioSciences Inc., today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology.
› Verified 3 days ago
| Sparrow Hospice Services Location: 1210 West Saginaw Street, Lansing, Michigan, 48915 Phone: (517) 886-8470 |
| Hospice Of Lansing Location: 3186 Pine Tree Road, Lansing, Michigan, 48911 Phone: (517) 886-8470 |
| Compassus - Lansing Location: 801 South Waverly Road Suite 200, Lansing, Michigan, 48917 Phone: (517) 886-8470 |